PaxMedica(PXMD) - 2023 Q3 - Quarterly Report

Financial Performance - As of September 30, 2023, the accumulated deficit of Paxmedica, Inc. was approximately $46.1 million[127]. - For the three months ended September 30, 2023, total operating expenses were $4.36 million, compared to $2.69 million for the same period in 2022, representing a 62% increase[140]. - The net loss for the three months ended September 30, 2023, was $5.05 million, compared to a net loss of $11.46 million for the same period in 2022, indicating a 56% improvement[140]. - The company incurred a net loss of approximately $12.4 million for the nine months ended September 30, 2023, compared to a net loss of $9.6 million for the same period in 2022[154]. - Net cash used in operating activities for the nine months ended September 30, 2023, was $8.2 million, primarily due to the net loss adjusted for non-cash expenses[160]. - The company had a cash balance of approximately $1.2 million as of September 30, 2023, raising concerns about its ability to continue as a going concern[165]. Research and Development - Research and development expenses for the three months ended September 30, 2023, were $1.94 million, a significant increase from $327,268 in the same period in 2022[140]. - Research and development expenses for the nine months ended September 30, 2023, were approximately $2.7 million, up from $1.5 million in 2022, reflecting a $1.2 million increase[149]. - The estimated aggregate costs for research and development activities related to the filing of an NDA for HAT and an IND for ASD are approximately $10.3 million[145]. - Research and development expenses primarily consist of salaries, benefits, and costs associated with clinical studies, with significant payments made to third parties for product development[183]. - Clinical trial costs are a significant component of research and development expenses, with costs recognized based on the completion percentage and contract milestones[179]. - The company periodically evaluates estimates related to clinical trial costs to determine if adjustments are necessary based on data from third-party contractors[182]. Financing Activities - During the nine months ended September 30, 2023, Paxmedica received net proceeds of approximately $5.4 million from the issuance of 0.2 million shares of common stock under an equity purchase agreement[128]. - The company issued a convertible promissory note in February 2023 with a principal balance of $3.7 million, receiving approximately $2.5 million net of expenses[129]. - The company received net proceeds of approximately $5.4 million from the issuance of 0.2 million shares of common stock in connection with its equity purchase agreement with Lincoln Park Capital[155]. - The outstanding principal balance of the 2023 Notes was approximately $2.9 million as of September 30, 2023[157]. Agreements and Future Plans - An exclusive distribution agreement with Vox Nova, LLC includes an upfront exclusivity fee of $0.5 million and potential additional payments of up to $2.0 million based on regulatory approval[132]. - The company is pursuing a New Drug Application for PAX-101, with a filing expected in the second half of 2024 following a type-B meeting with the FDA[135]. - The company anticipates significant increases in general and administrative expenses due to costs associated with operating as a public company[139]. Stock and Compensation - The company recognizes convertible notes at fair value, with changes in fair value reflected in the condensed statements of operations[178]. - The company has elected to use the fair value option for its convertible notes, which does not accrue interest and recognizes direct costs in general and administrative expenses[178]. - Stock-based compensation is expensed over the requisite service period based on estimated grant-date fair value, with actual forfeitures accounted for as they occur[173]. - The expected term for options is calculated using a simplified method, averaging the vesting term and the contractual period, typically 10 years[180]. - The expected volatility for stock options is based on historical volatility of comparable publicly traded companies, as the company lacks sufficient trading history[180]. - The company has not paid dividends on its common stock and does not expect to do so in the foreseeable future, using an expected dividend yield of zero[180]. General and Administrative Expenses - General and administrative expenses for the nine months ended September 30, 2023, were approximately $9.0 million, an increase of $4.9 million compared to $4.1 million for the same period in 2022[148]. - Other expense for the nine months ended September 30, 2023, was approximately $0.6 million, a decrease from $4.0 million in the same period in 2022[153].